L'intérêt à découvert pour Theriva Biologics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Theriva Biologics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Theriva Biologics (AMEX:TOVX) Stock, Rapport sur les intérêts à découvert

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics Inc

IonQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares are bouncing around in Thursday&#8217;s after-hours session after the company announced it reached a significant milestone in developing networked <a href="https://www.benzinga.com/pressreleases/24/10/b41173403/ionq-demonstrates-remote-ion-ion-entanglement-a-significant-milestone-in-developing-networked-quan">quantum systems at scale</a>.
What Happened: After the market close on Thursday, IonQ said it successfully demonstrated remote ion-ion entanglement, crossing off another milestone of its scaling strategy.
IonQ announced it achieved ion-photon entanglement in February. The remote ion-ion entanglement marks the second of four significant milestones required to develop photonic interconnects and take a foundational step towards quantum networking.
&#8220;IonQ&#8217;s north star remains scalability at high performance, and the progress we&#8217;ve made towards photonic interconnects ensures our customers will have access to large quantum systems capable of tackling the most complex problems,&#8221; said Peter Chapman, president and CEO of IonQ.
&#8220;We&#8217;re consistently making significant headway on our technical roadmap, and customers across academia and business recognize the unique value IonQ&#8217;s systems bring as we near the point of commercial quantum advantage.&#8221;
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41037763/kamala-harris-strengthens-crypto-stance-the-us-will-remain-dominant-in-ai-and-quantum-comp">Kamala Harris Strengthens Crypto Stance: The US Will &#8216;Remain Dominant In AI And Quantum Computing, Blockchain, And Other Emerging Technologies&#8217;</a>
The news comes less than a week after the company <a href="https://www.benzinga.com/markets/equities/24/09/41071006/why-is-ionq-stock-trading-higher-on-friday">announced</a> that it signed a $54.5 million contract with the U.S. Air Force Research Lab and said it remains on track to nearly double its revenue for the third year in a row. IonQ shares are up about 15% since the announcement. 
IonQ is scheduled to <a href="https://x.com/IonQ_Inc/status/1840843273352679778">host a session</a> with data software company Evidentli on Oct. 11. The session will focus on the transformational potential quantum computing offers to the pharmaceutical industry. 
According to the <a href="https://www.eventbrite.com.au/e/generative-ai-20-for-data-harmonisation-and-federated-analytics-tickets-1026755763127">event listing</a>, presenters will talk about how new generative AI approaches can transform real-world data 250 times faster than current methods.
IONQ Price Action: <a href="http://benzinga.com/quote/ionq">IonQ shares</a> closed Thursday up 0.54%. The stock was up another 0.54% in after-hours, trading at $9.30 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of IonQ.

News

After-Hours Center

Movers

Tech

IONQ

What's Going On With IonQ Stock Thursday?

Retail industry veteran Seth Golden recently warned that, according to a widely used oscillator Williams %R, the <a href="https://www.benzinga.com/topic/s-p-500">S&amp;P 500</a> has been overbought for an entire year.
Golden, a hedge fund consultant who previously worked for household names such as Target and now-defunct Bed Bath &amp; Beyond, pointed out that this is just the 23rd time in history that this has occurred.
Based on historical data he shared in a post on <a href="https://x.com/SethCL/status/1841808020705075700">X</a>, he pointed out that when this happened, it continued the same trend for the rest of the year — posting a fourth-quarter median return of 5.29%.
<a href="https://www.benzinga.com/11/04/1035270/pros-and-cons-of-williams-r-indicator">Williams %R</a>, often dubbed the Williams percent range, is a momentum indicator. It measures the overbought and oversold levels on a scale from 0 to 100. A reading above -20 is overbought and a reading below -80 is oversold.
Golden used a 28-month parameter, an industry standard for this indicator.
See Also: <a href="https://www.benzinga.com/general/travel/24/10/41172625/will-airlines-soar-or-stall-what-insider-trades-say-about-airline-industrys-future">Will Airlines Soar Or Stall? What Insider Trades Say About Industry&#8217;s Future</a>
Looking deeper into the list of overbought stocks brings an interesting mix of domestic and foreign catalysts.
Lockheed Martin's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) presence on this list is unsurprising. The leading aerospace and defense manufacturer&#8217;s stock hit a fresh all-time high, reaching $609 and giving it a market cap of over $144B. The firm benefits from increased defense spending during <a href="https://www.benzinga.com/news/global/24/10/41126038/iran-attacks-israel-with-missiles-middle-east-tensions-escalates-s-p-500-stocks-bitcoin-fall-as-oil">escalating global conflicts</a> and with a <a href="https://www.benzinga.com/news/earnings/24/10/41164528/lockheed-wins-2-1b-contract-to-aid-trident-ii-d5-missile-program">new multi-billion U.S. Navy contract</a> it landed last Thursday. Despite a hefty $19.26B debt, the firm has the balance sheet to easily manage it, plus pay a reliable 2.1% dividend. Its Williams %R overbought score is currently -11.41.
Next on the list is Lowe's Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), a North Carolina-based retailer specializing in home improvement. It recently hit a new all-time high of $274.16. Along with other home improvement stocks, Lowe <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41008424/lowes-set-for-delayed-benefits-from-macro-demand-improvements-says-optimistic-analy">experienced a surge</a> following the FED's rate cut. Still, this strong performance is surprising, given the firm's revenue decline of nearly 10% year over year and dimmed future growth projections. Its Williams %R overbought score is currently -5.71.
Entergy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) has been a utility industry standout, delivering an almost 30% return year-to-date. Despite such numbers, the stock trades at a reasonable P/E ratio of 15.9x, below some of its peers like Exelon or FirstEnergy.
Entergy provides electric power to the southern U.S. states, benefiting from rapid energy growth in states such as Texas. Investors expect the company to scale with its target market, with a booming population and increased industrial activity prompting higher energy consumption. The stock's Williams %R overbought score currently stands at -7.41.
Read Next: <a href="https://www.benzinga.com/government/24/10/41172781/oil-prices-rally-biden-confirms-us-discussions-with-israel-about-striking-iran-facilities"> •&nbsp;Oil Prices Rally: Biden Confirms US &#8216;Discussions&#8217; With Israel About Striking Iran Facilities</a>
Photo: Shutterstock

Analyst Color

Equities

Markets

Trading Ideas

Why S&P 500's Year-Long Overbought Signal Has This Expert Talking, Plus 3 Stocks To Watch

Restricted subsidiary Calumet Montana Refining, LLC (&quot;CMR&quot;) entered into a new agreement with Stonebriar in which CMR sold certain of its assets to Stonebriar for&nbsp;$150 million&nbsp;and leased back the same assets.

CLMT

Calumet Reveals Series Of Related Agreements With Stonebriar Commercial Finance

Management

NewMarket Says William Skrobacz Is Stepping Down From His Role As Vice President And CFO, Effective December 31, 2024, As He Intends To Retire From Company In 2025; Timothy Fitzgerald Named As Successor

ConRes Test Equipment generates approximately&nbsp;$12 million&nbsp;in annual sales and is expected to be immediately accretive to DSG&#39;s adjusted EBITDA margins on a go-forward basis.
The transaction will be funded through DSG&#39;s existing cash and availability under its credit agreement and is expected to close in the&nbsp;fourth quarter&nbsp;of 2024, subject to customary closing conditions.
This acquisition is not expected to be material for financial reporting purposes to DSG&#39;s results.

DSGR

Distribution Solutions Group's TestEquity Agrees To Acquire ConRes Test Equipment; No Terms Disclosed

Under the agreement, TSMC will contract turnkey advanced packaging and test services from Amkor in their planned facility in Peoria, Arizona.
TSMC will leverage these services to support its customers, particularly those using TSMC&#39;s advanced wafer fabrication facilities in Phoenix.
The close collaboration and proximity of TSMC&#39;s front-end fab and Amkor&#39;s back-end facility will accelerate overall product cycle times.

Contracts

AMKR

Amkor Technology, TSMC Sign MoU To Collaborate And Bring Advanced Packaging And Test Capabilities To Arizona

5 analysts have shared their evaluations of Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Liberty Energy and provided 12-month price targets. The average target is $23.6, accompanied by a high estimate of $26.00 and a low estimate of $20.00. Experiencing a 7.81% decline, the current average is now lower than the previous average price target of $25.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1727989298_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Liberty Energy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Derek Podhaizer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Luke Lemoine</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Liberty Energy. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Liberty Energy compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Liberty Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Liberty Energy's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LBRT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Liberty Energy analyst ratings.</a>
<h2>Delving into Liberty Energy's Background</h2>
Liberty Energy is an oilfield services company that provides hydraulic fracturing services—mainly pressure pumping—in major basins throughout North America. Its 2020 acquisition of Schlumberger's OneStim business segment made Liberty one of the largest pressure pumpers in North America. It also added wireline operations, two Permian frac sand mines, and an expanded technological portfolio.
<h3>Breaking Down Liberty Energy's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Liberty Energy's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -2.94%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Liberty Energy's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.35%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Liberty Energy's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.67%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Liberty Energy's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.42% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Liberty Energy's debt-to-equity ratio is below the industry average at 0.24, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

LBRT

Forecasting The Future: 5 Analyst Projections For Liberty Energy

Throughout the last three months, 10 analysts have evaluated Republic Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $212.5, a high estimate of $230.00, and a low estimate of $200.00. Surpassing the previous average price target of $205.00, the current average has increased by 3.66%.
<img src="https://www.benzinga.com/files/images/story/2024/1727989277_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Republic Servs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Schumm</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$200.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Patrick Tyler Brown</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$214.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Arthur Nagorny</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$211.00</td>
<td>$201.00</td>
</tr>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$211.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Kevin Chiang</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$208.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Michael Hoffman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$211.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$192.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Republic Servs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Republic Servs compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Republic Servs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Republic Servs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RSG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Republic Servs analyst ratings.</a>
<h2>Delving into Republic Servs's Background</h2>
Republic Services is the second-largest integrated provider of traditional solid waste services in the United States, operating roughly 207 active landfills and 246 transfer stations. The company serves residential, commercial, and industrial end markets. It also runs a sizable recycling operation in North America.
<h3>Key Indicators: Republic Servs's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Republic Servs showcased positive performance, achieving a revenue growth rate of 8.64% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Republic Servs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Republic Servs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.69% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.62%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.2.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 10 Analyst Ratings Have To Say About Republic Servs

Analysts' ratings for Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) over the last quarter vary from bullish to bearish, as provided by 16 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $243.81, a high estimate of $290.00, and a low estimate of $185.00. A decline of 2.16% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1727989255_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Applied Mat among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$185.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$217.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Sidney Ho</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$270.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$280.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$224.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Applied Mat. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Applied Mat compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Applied Mat's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Applied Mat's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AMAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Applied Mat analyst ratings.</a>
<h2>About Applied Mat</h2>
Applied Materials is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
<h3>Financial Milestones: Applied Mat's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Applied Mat's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.49% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Applied Mat's net margin is impressive, surpassing industry averages. With a net margin of 25.15%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Applied Mat's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.21% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.2%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.35, Applied Mat adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMAT

A Glimpse Into The Expert Outlook On Applied Mat Through 16 Analysts

Analysts' ratings for Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $141.55, a high estimate of $164.00, and a low estimate of $120.00. Surpassing the previous average price target of $132.33, the current average has increased by 6.97%.
<img src="https://www.benzinga.com/files/images/story/2024/1727989235_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Blackstone by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$163.00</td>
<td>-</td>
</tr>
<tr>
<td>Nicholas Watts</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Neutral</td>
<td>$134.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Brungardt</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$146.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$164.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$141.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$120.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$126.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$134.00</td>
<td>$143.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Blackstone. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blackstone compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Blackstone's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blackstone analyst ratings.</a>
<h2>Discovering Blackstone: A Closer Look</h2>
Blackstone is the world's largest alternative-asset manager with $1.076 trillion in total asset under management, including $808.7 billion in fee-earning assets under management, at the end of June 2024. The company has four core business segments: private equity (25% of fee-earning AUM and 28% of base management fees), real estate (37% and 42%), credit and insurance (29% and 23%), and multi-asset investing (9% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
<h3>A Deep Dive into Blackstone's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Challenges: Blackstone's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -6.92%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Blackstone's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 19.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Blackstone's ROE excels beyond industry benchmarks, reaching 6.45%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Blackstone's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.11%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Blackstone's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.73, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 11 Analyst Insights On Blackstone

Ratings for Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $219.14, with a high estimate of $235.00 and a low estimate of $204.00. This current average has decreased by 2.67% from the previous average price target of $225.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1727989225_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Waste Management is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$224.00</td>
<td>$229.00</td>
</tr>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$213.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$204.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Kevin Chiang</td>
<td>CIBC</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$213.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$229.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$235.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waste Management. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Waste Management compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Waste Management's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Waste Management's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waste Management analyst ratings.</a>
<h2>Unveiling the Story Behind Waste Management</h2>
WM ranks as the largest integrated provider of traditional solid waste services in the United States, operating 263 active landfills and about 332 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
<h3>Understanding the Numbers: Waste Management's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Waste Management showcased positive performance, achieving a revenue growth rate of 5.53% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Waste Management's net margin excels beyond industry benchmarks, reaching 12.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 9.35%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Waste Management's ROA excels beyond industry benchmarks, reaching 2.04%. This signifies efficient management of assets and strong financial health.
Debt Management: Waste Management's debt-to-equity ratio stands notably higher than the industry average, reaching 2.25. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Waste Management

During the last three months, 9 analysts shared their evaluations of Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $171.67, along with a high estimate of $199.00 and a low estimate of $144.00. A decline of 8.79% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1727989210_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Chart Industries's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$146.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Daniel Kutz</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Ati Modak</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$144.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$199.00</td>
<td>$199.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$151.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$147.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Eric Stine</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$199.00</td>
<td>$229.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$199.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Chart Industries. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Chart Industries compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Chart Industries's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Chart Industries's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GTLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Chart Industries analyst ratings.</a>
<h2>All You Need to Know About Chart Industries</h2>
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company.
<h3>Breaking Down Chart Industries's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Chart Industries showcased positive performance, achieving a revenue growth rate of 14.56% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Chart Industries's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.98%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Chart Industries's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.89%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Chart Industries's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.56%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.48, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GTLS

Navigating 9 Analyst Ratings For Chart Industries

OpenAI&#8216;s latest valuation of more than $150 billion, plus Nvidia Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) &#8220;watershed&#8221; partnership with Accenture Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>), indicates that the &#8220;AI tidal wave&#8221; of spending is hitting its next growth stage, according to a research note from <a href="https://www.benzinga.com/topic/daniel-ives">Wedbush analyst Dan Ives</a>.
Nvidia and Accenture announced an <a href="https://www.benzinga.com/markets/equities/24/10/41142895/accenture-and-nvidia-team-up-to-supercharge-global-ai-adoption-details">expanded partnership</a> on Wednesday to help enterprises rapidly scale <a href="http://benzinga.com/topic/ai">AI</a> adoption.
&#8220;Accenture will be a key player on the AI Revolution and this is a smart strategic partnership in our view that is the tip of the iceberg on the broader AI Revolution and demand adoption into 2025 and beyond,&#8221; Ives said.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41151741/nvidias-ai-leadership-to-drive-1-trillion-market-growth-with-accenture-partnership-">Nvidia&#8217;s AI Leadership To Drive $1 Trillion Market Growth, With Accenture Partnership Accelerating Adoption, Analyst Says</a>
AI starts with Nvidia, but the transformation is taking place across the broader tech space, Ives said. 
For every $1 spent on an <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41149666/nvidias-blackwell-gpu-sets-new-ai-benchmark-with-over-100-system-configurations-ana">Nvidia GPU</a>, there is an $8 to $10 multiplier across the tech sector, he adds. This reinforces Wedbush&#8217;s bullish view for tech stocks over the next year, especially when coupled with the news out of OpenAI this week.
OpenAI announced Wednesday that it secured $6.6 billion in new funding at a valuation of $157 billion. Ives called it &#8220;eye popping.&#8221; 
The company plans to use the funding to accelerate AI research, increase compute capacity and continue building tools to solve complex problems. 
Check This Out: <a href="https://www.benzinga.com/markets/equities/24/10/41142895/accenture-and-nvidia-team-up-to-supercharge-global-ai-adoption-details">Accenture And NVIDIA Team Up To Supercharge Global AI Adoption: Details</a>
Ives called OpenAI a &#8220;key foundational linchpin&#8221; of the AI thesis given that the company&#8217;s ChatGPT product acted as the world&#8217;s &#8220;iPhone moment&#8221; in terms of generative AI. 
&#8220;Now we are seeing a $1 trillion of AI Capex over the next three years as OpenAI has been the linchpin to AI success and adoption we are seeing at Nvidia, Microsoft, Google, and across the tech world,&#8221; Ives said. 
Ives noted that there is essentially a fourth Industrial Revolution taking place across <a href="https://www.benzinga.com/topic/chip-stocks">semiconductors</a>, software, infrastructure, smartphones and internet. He anticipates a tidal wave of AI spending on the buildout over the next 12 to 18 months. 
&#8220;We also believe OpenAI now has a much more functional corporate structure which is a positive for the broader tech industry given how important Altman &amp; Co. have become to the AI Revolution,&#8221; Ives said.
OpenAI is restructuring its core business into a for-profit corporation that won&#8217;t be controlled by its non-profit board. The OpenAI non-profit will reportedly remain in place and take a minority stake in the for-profit company, per Reuters.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41156902/elon-musk-says-openai-is-evil-after-chatgpt-parent-reportedly-asked-investors-not-to-invest-in-rival">Elon Musk Says &#8216;OpenAI Is Evil&#8217; After ChatGPT-Parent Reportedly Asked Investors Not To Invest In Rivals, Including xAI: Ark&#8217;s Cathie Wood Says It&#8217;s &#8216;Not True&#8217;&nbsp;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

NVDA

OpenAI's Latest 'Eye-Popping' Valuation Ignites Analyst Expectations For 'Tidal Wave' Of AI Spending

In the current market session, United Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) stock price is at $350.07, after a 0.68% decrease. However, over the past month, the company's stock went up by 0.02%, and in the past year, by 49.39%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1727988397_0.png" alt="Past Year Chart" />

<h3>United Therapeutics P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 61.21 in the Biotechnology industry, United Therapeutics Inc. has a lower P/E ratio of 16.2. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1727988397_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

UTHR

A Look Into United Therapeutics Inc's Price Over Earnings

Roku Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares moved higher, and Macquarie analyst Tim Nollen raised the price target on the stock from $72 to $90 on Thursday. Here's a look at <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40926894/roku-the-arms-dealer-of-streaming-gears-up-for-monetization-surge-says-analyst">what to know. </a>
The Details: The Macquarie analyst noted that the Roku Channel is gaining share with 1.7% of television time, and the company is making moves to monetize its user base of 84 million active accounts. 
Nollen pointed to Roku's new self-service Ads Manager tool as a way for smaller advertisers to find audiences on Roku. Ads Manager <a href="https://www.benzinga.com/markets/equities/24/09/40920634/roku-introduces-innovative-ads-manager-for-direct-to-consumer-brands-details">includes features</a> designed to draw e-commerce merchants like shoppable ads that allow consumers to complete purchases directly using their Roku remote.
Read Next: <a href="https://www.benzinga.com/news/24/10/41152629/what-happened-with-accenture-stock-today">What Happened With Accenture Stock Today?</a>
Nollen highlighted Ad Manager's solid CPM pricing strategy which is more shielded from pricing pressures faced by premium streaming platforms, like Netflix and Disney+.
The analyst added recent subscription price increases across streaming services that Roku hosts provide an additional catalyst for revenue growth. Macquarie expects revenue growth of between 14% and 15% in both fiscal year 2024 and 2025. 
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Roku shares have gained more than 15% over the past month and are trading above the stock's 50-day moving average of $65.05.&nbsp;
ROKU Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Roku shares ended Thursday's session 1.71% higher at $75.45.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122476/whats-going-on-with-microstrategy-stock">What&#8217;s Going On With MicroStrategy Stock?</a></li>
</ul>
Photo: Shutterstock

Entertainment

ROKU

What Happened With Roku Stock Today?

Currently, of its 198 stores, 186 stores are open for business, but a lack of internet access and other connectivity has limited transactions in many locations.&nbsp;

Guidance

IMKTA

Ingles Markets Says Hurricane Helene Has Impacted Both Stores And Distribution Center Operations;

Interactive Brokers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) launched a new range of political betting contracts, allowing U.S. investors to hedge their portfolios <a href="https://www.benzinga.com/pressreleases/24/10/b41165388/interactive-brokers-introduces-forecast-contracts-on-election-outcomes">against election-related risks.</a>
The contracts, which are available through the company's ForecastEx exchange, give traders the opportunity to speculate on the outcomes of the 2024 U.S. elections, including key races for the presidency and Congress.
Set to begin trading on Thursday at 5:15 p.m. ET, these contracts mark a significant expansion of Interactive Brokers&#8217; offerings, giving investors a new way to engage with political markets.
What Happened: Interactive Brokers introduced its election-based contracts just as KalshiEx, another major player in event-based markets, resumed accepting bets on the outcome of 2024 congressional races. 
This resumption comes after a federal appeals court lifted a ban that had prevented Kalshi from offering such contracts, which the Commodity Futures Trading Commission (CFTC) had contested, CNBC <a href="https://www.cnbc.com/2024/10/02/bets-on-congressional-races-allowed-cftc-appeals-court.html">reports</a>. While the CFTC continues its legal battle, Kalshi is moving forward with its congressional betting offerings.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41158370/wanna-put-your-money-on-trump-or-harris-crypto-based-polymarket-gets-competition-after-kal">Wanna Put Your Money On Trump Or Harris? Crypto-Based Polymarket Gets Competition After Kalshi Prevails In Court And Resumes Election Betting Contracts</a>
Alongside Kalshi&#8217;s offerings, Interactive Brokers&#8217; new Forecast Contracts give investors access to contracts on both U.S. Senate and House races, as well as the presidential election. 
These contracts allow users to bet on outcomes ranging from specific Senate races to whether the Democrats or Republicans will hold a majority in Congress. Additionally, the forecast contracts let investors trade their political insights with a simple "yes" or "no" position, with potential payouts determined by whether their predictions come true.
Why It Matters: This surge in political betting opportunities allows investors to hedge against political uncertainty, potentially protecting portfolios from election-driven market volatility. For KalshiEx, the legal decision provides a key opportunity to continue growing its market presence while regulatory challenges are ongoing.
With traders now eyeing pivotal races, speculation is heating up, particularly on the 2024 presidential election, where both Donald Trump and Vice President Kamala Harris are seen as major contenders, each currently holding a 49% chance of winning, <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41170754/donald-trump-is-now-level-with-kamala-harris-at-49-5-election-odds-after-september-rollerc">according to Polymarkets.</a> Meanwhile, KalshiEx's betting markets suggest the 2024 Senate could swing Republican, with 75% of bets predicting a GOP majority, CNBC reports.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41172310/vance-vs-walz-heres-how-many-people-watched-vp-debate">Vance Vs. Walz: Here&#8217;s How Many People Watched VP Debate</a></li>
</ul>
Photo: Shutterstock

Government

Sports Betting

Politics

IBKR

Interactive Brokers Rolls Out Election Contracts As Kalshi Resumes High-Stakes Congressional Bets

Trump Media & Technology Says Effective Sept 28, Andrew Northwall Resigned As COO; Plans To Transition COO Duties Internally

In this role, Scott will be responsible for AMN&#39;s finance and enterprise operating functions as the Company continues to evolve its model to be more automated and scaled.
Scott&#39;s appointment follows AMN&#39;s recent announcement that Jeffrey Knudson will be stepping down from his role as CFO, effective November 8, 2024, to pursue an opportunity with a private company outside of the healthcare staffing industry.

AMN Healthcare Services Names Brian Scott As CFO And COO, Effective November 21, 2024; Scott Returns To AMN, Previously Serving As CFO From 2011 To 2021

<h3>Gainers</h3>
<ul>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock rose 51.3% to $0.76 during Thursday's after-market session. The company's market cap stands at $116.9 million. </li>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares increased by 11.57% to $0.27. The market value of their outstanding shares is at $15.4 million. </li>
<li>Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) shares rose 7.63% to $19.5. The company's market cap stands at $1.3 billion. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) stock moved upwards by 7.04% to $5.62. The company's market cap stands at $132.9 million. </li>
<li>Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) shares increased by 4.99% to $11.77. The company's market cap stands at $8.7 billion. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares increased by 4.63% to $1.58. The market value of their outstanding shares is at $133.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock fell 8.5% to $1.18 during Thursday's after-market session. The company's market cap stands at $2.5 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares decreased by 7.57% to $0.34. The company's market cap stands at $7.1 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock fell 7.41% to $0.5. The market value of their outstanding shares is at $4.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock declined by 5.03% to $1.7. The market value of their outstanding shares is at $2.3 million. </li>
<li>2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) stock fell 4.85% to $4.52. The company's market cap stands at $232.7 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares fell 4.52% to $1.69. The company's market cap stands at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIMD

AVGR

BBLG

CTCX

IPSC

OTLK

PHAT

RENB

ROIV

TOVX

TSVT

12 Health Care Stocks Moving In Thursday's After-Market Session

Theriva biologics announces 1:25 reverse stock split

These are the upcoming stock splits for the week of August 26 to August 30, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a corpo...

Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested

Theriva Biologics ($TOVX) is making noise in the field of immuno-oncology, supported by a promising pipeline. The stock is up 79% in the past few d...

Theriva Biologics (TOVX) Is Making Noise With a Promising Pipeline

Theriva Biologics files for common stock offering

Theriva Biologics ( ($TOVX) ) has provided an update. Theriva Biologics, Inc. has received a €2.28 million boost from the Spanish government to enh...

Theriva Biologics Secures Funding for Viral Therapy Innovation

Theriva Biologics ( ($TOVX) ) has shared an update. Theriva Biologics, Inc. is actively engaging with investors and discussing their lead product c...

Theriva Biologics Advances VCN-01 in VIRAGE Phase 2b Trial

Theriva Biologics dips 11%, prices 2.5M equity offering

Theriva Biologics dips 11%, prices $2.5M equity offering

An update from Theriva Biologics ( ($TOVX) ) is now available. Theriva Biologics, Inc. announced positive results from their Phase 1b/2a trial of S...

Theriva Biologics Advances SYN-004 in Clinical Trial

Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients

FBRX

GDEV

OBLG

Screenshot 2024-08-23 at 5.34.20 PM

Biotech

General

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-28 at 6.54.06 PM

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Health Care

Press Releases

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Earnings

Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

Theriva Biologics Announces Reverse Stock Split

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Aditxt

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apollomics

Aptevo Therapeutics

180 Life Sciences

Bio-Path Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Entero Therapeutics

Genprex

GRI Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Scorpius Holdings

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Tharimmune

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

WIIM

Theriva Biologics shares are trading higher after the company announced the Data and Safety Monitoring Committee's review outcome for its Phase 1b/2a clinical trial of SYN-004. The DSMC has recommended the study proceed to enroll cohort 3.

Comments

Theriva Biologics

Intérêt court

Theriva Biologics (AMEX:TOVX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL